Takeda Pharmaceutical Company Limited (TAK)
NYSE: TAK · Real-Time Price · USD
15.34
-0.08 (-0.52%)
Jul 3, 2025, 1:00 PM - Market closed
Takeda Pharmaceutical Employees
Takeda Pharmaceutical Company had 47,455 employees as of March 31, 2025. The number of employees decreased by 1,826 or -3.71% compared to the previous year.
Employees
47,455
Change (1Y)
-1,826
Growth (1Y)
-3.71%
Revenue / Employee
$644,718
Profits / Employee
$15,188
Market Cap
47.98B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Mar 31, 2025 | 47,455 | -1,826 | -3.71% |
Mar 31, 2024 | 49,281 | 186 | 0.38% |
Mar 31, 2023 | 49,095 | 1,748 | 3.69% |
Mar 31, 2022 | 47,347 | 248 | 0.53% |
Mar 31, 2021 | 47,099 | -396 | -0.83% |
Mar 31, 2020 | 47,495 | -2,083 | -4.20% |
Mar 31, 2019 | 49,578 | 22,348 | 82.07% |
Mar 31, 2018 | 27,230 | -2,670 | -8.93% |
Mar 31, 2017 | 29,900 | -1,268 | -4.07% |
Mar 31, 2016 | 31,168 | -160 | -0.51% |
Mar 31, 2015 | 31,328 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 94,300 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
TAK News
- 5 days ago - Takeda Announces U.S. FDA Approval of GAMMAGARD LIQUID ERC, the Only Ready-to-Use Liquid Immunoglobulin Therapy with Low Immunoglobulin A (IgA) Content1 - Business Wire
- 10 days ago - Takeda Announces New Assignments of Directors - Business Wire
- 4 weeks ago - European Commission Approves ADCETRIS® (brentuximab vedotin) for the Treatment of Adult Patients with Newly Diagnosed Stage IIb/III/IV Hodgkin Lymphoma in Combination with ECADD - Business Wire
- 4 weeks ago - Protagonist and Takeda Announce ASCO Plenary Presentation Highlighting Full 32-Week Results from Phase 3 VERIFY Study of Rusfertide, Showing Reductions in Phlebotomy, Improved Hematocrit Control in Polycythemia Vera - Business Wire
- 5 weeks ago - Takeda and Nature Announce Call for Applications Now Open for 2026 Innovators in Science Award - Business Wire
- 7 weeks ago - The New England Journal of Medicine Publishes Data from Phase 2b Trial of Oral Orexin Receptor 2 Agonist Oveporexton (TAK-861) in People with Narcolepsy Type 1 - Business Wire
- 7 weeks ago - Takeda Pharmaceuticals Caps A Strong Year, Guidance Suggests Dividend Is On The Rise - Seeking Alpha
- 2 months ago - Takeda Pharmaceutical Company Limited (TAK) Q4 2024 Earnings Call Transcript - Seeking Alpha